Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer

Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage in 75% of cases. The cancer antigen (CA) 125 is use...

Full description

Bibliographic Details
Published in:	Radiology and Oncology
Main Authors:	Merlo Sebastjan, Besic Nikola, Drmota Eva, Kovacevic Nina
Format:	Article
Language:	English
Published:	Sciendo 2021-08-01
Subjects:	ovarian cancer tumour marker ca-125 primary debulking surgery neoadjuvant chemotherapy
Online Access:	https://doi.org/10.2478/raon-2021-0013

Similar Items

CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals
by: Cheng Li, et al.
Published: (2024-05-01)

The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers
by: G. N. A. Winarno, et al.
Published: (2020-07-01)

Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India
by: Debabrata Barmon, et al.
Published: (2023-10-01)

Risk-stratified CA125 screening integrating CA125 trajectories, trajectory-specific progression and transvaginal ultrasound for ovarian cancer
by: Hongyuan Duan, et al.
Published: (2024-10-01)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
by: Jorge A. Alegría-Baños, et al.
Published: (2021-07-01)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
by: Elham Saffarieh, et al.
Published: (2022-08-01)

Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)
by: E. V. Sibirskaya, et al.
Published: (2024-05-01)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
by: Upasana Baruah, et al.
Published: (2015-01-01)

Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125
by: Szu-Ting Yang, et al.
Published: (2023-11-01)

Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction
by: Mackenzie Cummings, et al.
Published: (2022-04-01)

Correlation of Cytohistlogical Expression and Serum Level of Ca125 in Ovarian Neoplasm
by: Chhanda Das, et al.
Published: (2014-03-01)

NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
by: A. E. Solopova, et al.
Published: (2016-09-01)

CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
by: Wang Fang, et al.
Published: (2013-02-01)

Prognostic value of CT-PCI and CA-125 changes following neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A retrospective study from Vietnam
by: Ty Van Ngo, et al.
Published: (2025-10-01)

Predictive Value of the CA-125 Elimination Rate Constant K (KELIM) in Predicting Progression-Free Survival and Overall Survival in Epithelial Ovarian Cancer
by: Necim Yalcin, et al.
Published: (2025-07-01)

Determination of Serum CA125 and evaluate its efficiency as screening tool For Early Detection of Ovarian Tumors
by: Baghdad Science Journal
Published: (2015-03-01)

The Role of CA‐125 in the Management of Ovarian Cancer: A Systematic Review
by: Zohre Momenimovahed, et al.
Published: (2025-03-01)

The Value of CA125 and CA19-9 in the Diagnosis of Stage Ⅲ and Ⅳ Endometriosis
by: Wenwen Zhang, et al.
Published: (2024-02-01)

The Role of Salivary and Serum Ca125 and Routine Blood Tests in Patients with Ovarian Malignancies
by: Ante Vuković, et al.
Published: (2021-01-01)

Role of CA125 in the Diagnosis of Acute Appendicitis
by: Barış Sevinç, et al.
Published: (2017-06-01)

Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer
by: Kheyal Azam Khalil, et al.
Published: (2025-03-01)

Ovarian Fibroma with Meigs Syndrome associated with Elevated CA125 - A Rare Case
by: Prasad. K. Shetty, et al.
Published: (2010-07-01)

Research progress of CA125 in endometriosis: Teaching an old dog new tricks
by: Yonghua Chen, et al.
Published: (2022-12-01)

Akut apandisitte Ca125, CA19.9 ve karsinoembriyonik antijen gibi tümör belirteçlerinin rolü
by: Sevil Kurban, et al.
Published: (2015-09-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

The impact of multiple neoadjuvant chemotherapy cycles in patients with advanced epithelial ovarian cancer: A single center experience
by: Wala Mehros, et al.
Published: (2025-01-01)

Nomogram development for predicting ovarian tumor malignancy using inflammatory biomarker and CA-125
by: Gatot Nyarumenteng Adhipurnawan Winarno, et al.
Published: (2024-07-01)

Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer
by: Yue Jia, et al.
Published: (2024-02-01)

Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas
by: Ji Hui Choi, et al.
Published: (2018-05-01)

The Role of CA-125 Levels as a Prognostic Indicator for Response to Medical Treatment in Fallopian Ectopic Pregnancy
by: Mohammad Eslami Vaghar
Published: (2024-01-01)

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
by: Charles J. Dunton, et al.
Published: (2021-08-01)

Evaluating Specivity, Sensitivity, Positive and Negative Predictive Values of CA125 for Diagnosing Ovarian Cancer
by: Elahe Fini, et al.
Published: (2021-08-01)

Evaluating Specivity, Sensitivity, Positive and Negative Predictive Values of CA125 for Diagnosing Ovarian Cancer
by: Elahe Fini, et al.
Published: (2021-08-01)

Thrombocytosis and CA125 as Predictor of Malignancy in Gynaecological Pelvic Mass
by: Najmah M. Miran
Published: (2018-10-01)

Perspectives on Ovarian Cancer 1809 to 2022 and Beyond
by: Frank G. Lawton, et al.
Published: (2022-03-01)

Primary versus interval debulking surgery in the management of ovarian cancer patients, current data summary
by: Victoria Psomiadou, et al.
Published: (2022-04-01)

Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
by: Fei Wang, et al.
Published: (2018-11-01)

Correlation of Tumor Marker Cancer Antigen (CA-125) against Hemoglobin, Leucocytes, and Platelet Lymphocyte Ratio in Ovarian Cancer Patients at RSUD ULIN Banjarmasin
by: hermin sabarudin
Published: (2018-09-01)

Characterization of M11-like and OC125-like Monoclonal Antibody Binding to CA125 Tandem Repeats
by: Trisha Nair, et al.
Published: (2025-09-01)